Trial Profile
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases
- Focus Registrational; Therapeutic Use
- Acronyms INBUILD
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 22 Dec 2023 Results investigating the effects of nintedanib on the symptoms and impact of pulmonary fibrosis in patients with progressive pulmonary fibrosis (PPF) using the Living with Pulmonary Fibrosis (L-PF) questionnaire, published in the European Respiratory Journal
- 26 Sep 2023 Results assessing efficacy of nintedanib on slowing decline in FVC across subgroups in the trial by the baseline characteristics over 52 weeks compared with placebo published in the Advances in Therapy.
- 13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society